Caroline Block
Overview
Explore the profile of Caroline Block including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlam I, Hirko K, Shveid D, Abuali I, Sewaralthahab S, Nakhils F, et al.
JCO Glob Oncol
. 2024 Dec;
10:e2400307.
PMID: 39705637
Purpose: Trimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM), and postmastectomy radiation therapy....
2.
Jacobson J, Rompelman G, Chen A, Morrison-Ma S, Murray L, Ferzoco M, et al.
JCO Oncol Pract
. 2024 Apr;
20(8):1115-1122.
PMID: 38608224
Purpose: Several allelic variants of the gene encoding dihydropyrimidine dehydrogenase (DPD) are associated with impaired metabolism of the systemic fluoropyrimidine fluorouracil (5FU) and its oral prodrug, capecitabine, which elevates the...
3.
Garrido-Castro A, Regan M, Niman S, Nakhlis F, Remolano C, Rosenbluth J, et al.
NPJ Breast Cancer
. 2023 Jun;
9(1):50.
PMID: 37268625
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20-30% of cases, with one-third of cases demonstrating HER2-positivity. There...
4.
Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, et al.
Oncologist
. 2021 Sep;
26(11):927-933.
PMID: 34472667
Background: In early trials, hypersensitivity reactions (HSRs) to paclitaxel were common, thus prompting the administration of antihistamines and corticosteroids before every paclitaxel dose. We tested the safety of omitting corticosteroids...
5.
Hirko K, Regan M, Remolano M, Schlossman J, Harrison B, Yeh E, et al.
Am J Clin Oncol
. 2021 Jun;
44(9):449-455.
PMID: 34149037
Objectives: Dermal lymphatic invasion (DLI) with tumor emboli is a common pathologic characteristic of inflammatory breast cancer (IBC), although its presence is not required for diagnosis. We examined whether documented...
6.
Ghazani A, Breen K, Dwan M, Barletta J, Vatnick D, Stokes S, et al.
Am J Case Rep
. 2020 Dec;
21:e927415.
PMID: 33361738
BACKGROUND RET p.V804M is a known activating oncogenic variant that confers an increased risk for medullary thyroid carcinoma (MTC). Based on age-specific penetrance, the American Thyroid Association (ATA) categorizes this...
7.
White R, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, et al.
Breast J
. 2020 Sep;
26(9):1688-1694.
PMID: 32875655
There are scant data identifying epidemiologic characteristics among individuals diagnosed with inflammatory breast cancer (IBC), which is considered the most aggressive subtype of breast cancer. The purpose of this study...
8.
Vaz-Luis I, Barroso-Sousa R, Di Meglio A, Hu J, Rees R, Sinclair N, et al.
J Clin Oncol
. 2020 Apr;
38(21):2390-2397.
PMID: 32330102
Purpose: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the...
9.
Ozanne E, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, et al.
Cancer Epidemiol Biomarkers Prev
. 2012 Oct;
22(1):146-9.
PMID: 23093547
The American Cancer Society (ACS) guidelines define the appropriate use of MRI as an adjunct to mammography for breast cancer screening. Three risk assessment models are recommended to determine if...
10.
Ozanne E, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A, et al.
Breast J
. 2009 Mar;
15(2):155-62.
PMID: 19292801
Despite advances in identifying genetic markers of high risk patients and the availability of genetic testing, it remains challenging to efficiently identify women who are at hereditary risk and to...